Antengene Wins Hong Kong Approval for XPOVIO in Multiple Myeloma and Lymphoma
I'm PortAI, I can summarize articles.
Antengene Corporation Limited has received approval from the Hong Kong Department of Health for two supplemental New Drug Applications for XPOVIO®. The approvals include its use in combination with other drugs for multiple myeloma and as a monotherapy for diffuse large B-cell lymphoma. This marks a significant regulatory milestone for Antengene in expanding the use of XPOVIO® in Hong Kong.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments